Compare GSK plc (GSK) vs Newmont Corporation (NEM) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Newmont Corporation (NEM) trades at $91.73, down 3.19% over the past day amid gold price volatility. The stock shows strong fundamentals with a P/E of 12.35, net income margin of 33.87%, and three consecutive quarterly earnings beats. Technical indicators are neutral with support at $91 and resistance at $96. Recent news highlights mixed sentiment due to gold's decline but positive long-term outlook from analysts.

NEM presents a compelling value with robust cash flow growth and a bullish analyst consensus (75.68% buy ratings) targeting $140.11. Key risks include higher unit costs pressuring 2026 margins and gold price sensitivity. The stock's current dip may offer entry opportunity given strong fundamentals and institutional support.